KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Financing Activities (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Cash from Financing Activities for 15 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 44.75% to $8.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2025, down 25.12% year-over-year, with the annual reading at $9.1 million for FY2025, 25.12% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $8.5 million at Supernus Pharmaceuticals, down from $21.1 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $80.2 million in Q1 2023, with the low at -$478.9 million in Q2 2023.
  • Average Cash from Financing Activities over 5 years is -$25.9 million, with a median of $2.0 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities surged 6921.88% in 2021, then crashed 21169.78% in 2023.
  • Over 5 years, Cash from Financing Activities stood at -$136.7 million in 2021, then skyrocketed by 102.07% to $2.8 million in 2022, then plummeted by 61.4% to $1.1 million in 2023, then skyrocketed by 439.38% to $5.9 million in 2024, then skyrocketed by 44.75% to $8.5 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $8.5 million, $21.1 million, and $935000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.